Exabis Library
Welcome to the e-CCO Library!
P724: Upadacitinib is Effective and Safe in Tofacitinib-Experienced Patients with Ulcerative Colitis: A Prospective Real-World Experience
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P724: Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P725 Trends in biologic use prior to resective surgery for inflammatory bowel disease: A Canadian population-based study 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P725: A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P725: Ileal pouch excision: A contemporary observational cohort
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P725: Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination rates
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P725: The impact of an integrated model of care for patients with inflammatory bowel disease in Canada
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P726: Fecal calprotectin and quality of life questionnaires are responsive to change in pouch disease activity following antibiotic therapy—results from a prospective clinical trial
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P726: High mortality risk after first hospital admission for inflammatory bowel disease: a nationwide registry linkage study
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P726: Metalloproteinase 3: A new marker for assessing loss of response to infliximab in IBD
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P726: Trough levels of infliximab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn’s disease on infliximab maintenance therapy 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P727 Small bowel capsule endoscopy impact on therapeutic decisions in established Crohn’s disease: Analysis of a real-world data 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P727: Change in Crohn's disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P727: Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies
 2023
 ECCO’23 Copenhagen
 Friday, 14 July 2023, 11:12 AM
P727: Efficacy of vedolizumab (VDZ) by disease localisation in Crohn’s disease
 2018
 ECCO '18 Vienna
 Thursday, 21 February 2019, 9:14 AM
P727: Quality of life and disease activity in children and adolescents with inflammatory bowel disease 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM
P728 Comparative assessment of faecal microbiota transplantation and current therapies as induction treatment for active refractory ulcerative colitis: A systematic review and network meta-analysis 
 2020
ECCO'20 Vienna
 Thursday, 30 January 2020, 10:12 AM
P728: Changes in the use of biologics in the treatment of IBD patients over time. Results from a comprehensive Norwegian registry study
 2017
 ECCO '17 Barcelona
 Wednesday, 20 February 2019, 10:36 AM
P728: Effectiveness and quality of life (QoL) of Ustekinumab (UST) therapy in a Real-world Setting in Germany – First Results of the RUN-CD Study 
 2019
ECCO '19 Copenhagen
 Friday, 22 February 2019, 9:41 AM